Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-12-06

Clinical Trial Update: Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate [Phase 2]

View source ↗

Summary

Phase IIb dose-ranging trial of BMS-945429 in methotrexate-not-responsive rheumatoid arthritis completed; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BMS-945429

Snippet

Sponsor: CSL Behring | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED | Results posted: 2021-12-06